Net Loss Per Share

6 Months Ended

Jun. 30, 2025

The following table sets forth the computation of basic and diluted net loss per share for the three and six months ended June 30, 2025, and 2024 (in thousands, except number of shares):


	Three months ended June 30,				Six months ended June 30,
	2025		2024		2025		2024
Numerator:
Net loss	$	(21,126)	$	(16,943)	$	(40,784)	$	(32,463)
Net loss attributable to noncontrolling interest	2		12		12		43
Net loss attributable to Barinthus Biotherapeutics plc shareholders	$	(21,124)	$	(16,931)	$	(40,772)	$	(32,420)
Denominator:
Weighted-average ordinary shares outstanding, basic	40,343,521		39,041,111		40,304,584		38,907,296

Weighted-average ordinary shares outstanding, diluted	40,343,521		39,041,111		40,304,584		38,907,296
Net loss per share attributable to ordinary shareholders, basic	$	(0.52)	$	(0.43)	$	(1.01)	$	(0.83)
Net loss per share attributable to ordinary shareholders, diluted	$	(0.52)	$	(0.43)	$	(1.01)	$	(0.83)

Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share, as the inclusion of all potential ordinary share equivalents outstanding would have been anti-dilutive. As of June 30, 2025, 7,625,728 potential ordinary shares issuable for stock options were excluded from the computation of diluted weighted-average shares outstanding because including these shares would have had an anti-dilutive effect (June 30, 2024: 7,779,884).